Immutep Limited
Immutep Limited (PRRUF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Immutep Limited (PRRUF), covering cash flow, earnings, and balance sheets.
Immutep Limited (PRRUF) Income Statement & Financial Overview
View the income breakdown for Immutep Limited PRRUF across both annual and quarterly reports.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $3.15M | $1.73M | $2.11M | $1.82M |
| Cost of Revenue | $25.33M | $21.11M | $20.44M | $924019.00 |
| Gross Profit | -$22.18M | -$19.38M | -$18.33M | $896169.00 |
| Gross Profit Ratio | -$7.05 | -$11.20 | -$8.68 | $0.49 |
| R&D Expenses | $25.33M | $21.11M | $20.44M | $9.82M |
| SG&A Expenses | $4.23M | $4.05M | $4.80M | $20.91M |
| Operating Expenses | $29.56M | $25.16M | $25.24M | $20.91M |
| Total Costs & Expenses | $54.90M | $46.27M | $45.67M | $21.83M |
| Interest Income | $3.14M | $1.88M | $2.00M | $635310.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $5414.00 |
| Depreciation & Amortization | $23477.00 | $1.08M | $929607.00 | $924019.00 |
| EBITDA | -$26.39M | -$22.35M | -$22.20M | -$19.07M |
| EBITDA Ratio | -$8.38 | -$12.91 | -$10.52 | -$11.49 |
| Operating Income | -$51.75M | -$44.54M | -$43.56M | -$21.83M |
| Operating Income Ratio | -$16.44 | -$25.73 | -$20.64 | -$11.99 |
| Other Income/Expenses (Net) | $29.37M | $23.05M | $22.34M | $2.56M |
| Income Before Tax | -$22.38M | -$21.49M | -$21.23M | -$19.27M |
| Income Before Tax Ratio | -$7.11 | -$12.41 | -$10.06 | -$10.59 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $1.00 |
| Net Income | -$22.38M | -$21.49M | -$21.23M | -$19.27M |
| Net Income Ratio | -$7.11 | -$12.41 | -$10.06 | -$10.59 |
| EPS | -$0.02 | -$0.02 | -$0.02 | -$0.02 |
| Diluted EPS | -$0.02 | -$0.02 | -$0.02 | -$0.02 |
| Weighted Avg Shares Outstanding | $1.45B | $1.21B | $1.19B | $921.55M |
| Weighted Avg Shares Outstanding (Diluted) | $1.45B | $1.22B | $1.19B | $921.55M |
Over the past four quarters, Immutep Limited demonstrated steady revenue growth, increasing from $1.82M in Q4 2023 to $3.15M in Q2 2025. Operating income reached -$51.75M in Q2 2025, maintaining a consistent -1644% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$26.39M, reflecting operational efficiency. Net income dropped to -$22.38M, with EPS at -$0.02. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan